^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR G724S |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report
Published date:
06/03/2022
Excerpt:
Here, we present an EGFR-mutated lung cancer patient with a 13-year history of anticancer treatment, in which EGFR ex.19 deletion (E746_S752 > V) and G724S mutations were detected….We choose dacomitinib as 14th line chemotherapy based on ex.19 deletion and G724S mutant EGFR structure and its penetration rate to cerebral fluid, which successfully prolonged her life by 6 months.
DOI:
10.1007/s10637-022-01264-0
